Skip to main content

Caxton Corp

13F filer · CIK 0001388551
Reported Aug 14, 2026
13F portfolio value$1.85MU.S. long equity reported on 13F
Positions9Not reported new · Not reported closed
Net flow last quarterNot reportedBuys minus sells
Top 10 positions weight87.4%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 20269 positions
SPCXSpace Exploration Technologies Corp$445K24.03%Not reportedNewQ2 2026
BRK.BBerkshire Hathaway Inc$377K20.35%Not reported+3.7%Q2 2015
GOOGLAlphabet Inc.$247K13.32%0.00%Not reportedQ3 2019
BXBlackstone Inc.$188K10.16%0.00%NewQ2 2026
KYTXKyverna Therapeutics, Inc.$110K5.94%0.02%-34.2%Q1 2024
LXEOLexeo Therapeutics, Inc.$79K4.26%0.02%+21.7%Q4 2023
XFORX4 Pharmaceuticals, Inc$72.7K3.92%0.02%Not reportedQ4 2025
IKTInhibikase Therapeutics, Inc.$57.8K3.12%0.02%Not reportedQ4 2024
ALXOAlx Oncology Holdings Inc$43.4K2.34%0.02%Not reportedQ1 2026
Q1 2026Reported May 14, 20267 positions
GLDSPDR Gold Trust$3.28M81.50%0.00%+9.5%Q2 2020
BRK.BBerkshire Hathaway Inc$348K8.66%Not reported+2.4%Q2 2015
KYTXKyverna Therapeutics, Inc.$162K4.03%0.03%Not reportedQ1 2024
LXEOLexeo Therapeutics, Inc.$80K1.99%0.02%Not reportedQ4 2023
XFORX4 Pharmaceuticals, Inc$64.2K1.60%0.02%Not reportedQ4 2025
IKTInhibikase Therapeutics, Inc.$47.8K1.19%0.02%Not reportedQ4 2024
ALXOAlx Oncology Holdings Inc$42K1.04%0.02%NewQ1 2026
Q4 2025Reported Feb 13, 202611 positions
GLDSPDR Gold Trust$2.76M64.50%0.00%-4.4%Q2 2020
BRK.BBerkshire Hathaway Inc$357K8.34%Not reported+9.1%Q2 2015
SYRESpyre Therapeutics, Inc.$292K6.83%0.01%NewQ4 2025
MNMDDefinium Therapeutics, Inc.$210K4.91%Not reported-41.9%Q1 2024
KYTXKyverna Therapeutics, Inc.$176K4.12%0.03%-18.3%Q1 2024
CMPXCompass Therapeutics, Inc.$158K3.70%0.02%-44.9%Q4 2022
LXEOLexeo Therapeutics, Inc.$138K3.24%0.02%-19.6%Q4 2023
XFORX4 Pharmaceuticals, Inc$62.2K1.45%0.02%NewQ4 2025
IKTInhibikase Therapeutics, Inc.$58.3K1.36%0.02%+73.6%Q4 2024
SABSSAB Biotherapeutics, Inc.$39.4K0.92%0.02%-3.7%Q3 2025
CNTXContext Therapeutics Inc.$27.1K0.63%0.02%Not reportedQ2 2024
Q3 2025Reported Nov 14, 202512 positions
RZLTRezolute, Inc.$18.7M81.70%2.18%+23.9%Q4 2020
GLDSPDR Gold Trust$2.59M11.33%0.00%+47.1%Q2 2020
BRK.BBerkshire Hathaway Inc$327K1.43%Not reported+3.0%Q2 2015
MNMDDefinium Therapeutics, Inc.$318K1.39%Not reported-20.7%Q1 2024
ELVNEnliven Therapeutics, Inc.$268K1.17%0.02%Not reportedQ2 2025
CMPXCompass Therapeutics, Inc.$187K0.82%0.03%+23.1%Q4 2022
BCAXBicara Therapeutics Inc.$173K0.76%0.02%Not reportedQ3 2024
KYTXKyverna Therapeutics, Inc.$138K0.60%0.05%Not reportedQ1 2024
LXEOLexeo Therapeutics, Inc.$115K0.50%0.03%Not reportedQ4 2023
IKTInhibikase Therapeutics, Inc.$26.6K0.12%0.02%Not reportedQ4 2024
SABSSAB Biotherapeutics, Inc.$22K0.10%0.02%NewQ3 2025
CNTXContext Therapeutics Inc.$17.8K0.08%0.02%Not reportedQ2 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.